Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Short Interest Update

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 2,524 shares, a decline of 71.7% from the November 30th total of 8,926 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 7,740 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 7,740 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Fidelity Disruptive Medicine ETF

A hedge fund recently raised its stake in Fidelity Disruptive Medicine ETF stock. Jane Street Group LLC boosted its holdings in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) by 0.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,382 shares of the company’s stock after acquiring an additional 499 shares during the quarter. Jane Street Group LLC owned 3.16% of Fidelity Disruptive Medicine ETF worth $1,567,000 as of its most recent SEC filing.

Fidelity Disruptive Medicine ETF Stock Performance

NASDAQ:FMED opened at $27.61 on Thursday. The firm has a market capitalization of $60.74 million, a PE ratio of 41.33 and a beta of 1.00. The stock’s fifty day moving average is $27.22 and its 200 day moving average is $25.30. Fidelity Disruptive Medicine ETF has a fifty-two week low of $20.69 and a fifty-two week high of $29.07.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.